Danny Rischin

31.5k total citations · 5 hit papers
369 papers, 15.4k citations indexed

About

Danny Rischin is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Danny Rischin has authored 369 papers receiving a total of 15.4k indexed citations (citations by other indexed papers that have themselves been cited), including 220 papers in Oncology, 125 papers in Otorhinolaryngology and 100 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Danny Rischin's work include Head and Neck Cancer Studies (123 papers), Cancer Immunotherapy and Biomarkers (59 papers) and Lung Cancer Treatments and Mutations (40 papers). Danny Rischin is often cited by papers focused on Head and Neck Cancer Studies (123 papers), Cancer Immunotherapy and Biomarkers (59 papers) and Lung Cancer Treatments and Mutations (40 papers). Danny Rischin collaborates with scholars based in Australia, United States and Canada. Danny Rischin's co-authors include June Corry, Lester J. Peters, Rodney J. Hicks, Richard Fisher, Benjamin Solomon, Richard J. Young, A. Feyereislova, Sandro Porceddu, Steven D. Averbuch and José Baselga and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Danny Rischin

353 papers receiving 15.0k citations

Hit Papers

Multi-Institutional Randomized Phase II Trial of Gefitini... 2002 2026 2010 2018 2003 2002 2010 2010 2018 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
    2003 2.4k citations Masahiro Fukuoka, Seiji Yano et al. Journal of Clinical Oncology profile →
  2. Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
    2002 683 citations José Baselga, Danny Rischin et al. Journal of Clinical Oncology profile →
  3. Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial
    2010 571 citations Danny Rischin, Richard J. Young et al. Journal of Clinical Oncology profile →
  4. Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
    2010 548 citations Lester J. Peters, Brian O’Sullivan et al. Journal of Clinical Oncology profile →
  5. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
    2018 336 citations Benjamin Solomon, Richard J. Young et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danny Rischin Australia 56 7.8k 6.2k 3.6k 3.1k 3.0k 369 15.4k
Jacek Jassem Poland 59 11.4k 1.5× 8.0k 1.3× 3.3k 0.9× 4.8k 1.5× 3.3k 1.1× 523 19.9k
Ezra E.W. Cohen United States 67 8.5k 1.1× 5.6k 0.9× 4.7k 1.3× 4.7k 1.5× 3.2k 1.1× 421 16.9k
Roger B. Cohen United States 56 9.2k 1.2× 5.9k 0.9× 3.9k 1.1× 5.4k 1.7× 3.4k 1.1× 328 17.5k
Merrill S. Kies United States 57 7.3k 0.9× 5.3k 0.9× 5.7k 1.6× 2.7k 0.9× 5.2k 1.7× 178 14.6k
Bonnie S. Glisson United States 61 7.7k 1.0× 4.6k 0.7× 5.9k 1.6× 4.0k 1.3× 5.0k 1.7× 275 14.8k
Andy Trotti United States 51 5.9k 0.8× 7.0k 1.1× 9.5k 2.7× 1.7k 0.5× 6.3k 2.1× 143 16.6k
Barbara Burtness United States 56 8.5k 1.1× 5.0k 0.8× 5.0k 1.4× 4.4k 1.4× 3.7k 1.2× 363 16.0k
Lester J. Peters United States 56 4.1k 0.5× 4.0k 0.6× 4.4k 1.2× 1.9k 0.6× 3.7k 1.3× 181 12.2k
Lisa Licitra Italy 63 8.1k 1.0× 4.3k 0.7× 6.2k 1.7× 3.1k 1.0× 5.9k 2.0× 447 16.0k
M. Bolla France 50 4.6k 0.6× 16.6k 2.7× 2.8k 0.8× 1.7k 0.5× 5.1k 1.7× 231 22.9k

Countries citing papers authored by Danny Rischin

Since Specialization
Citations

This map shows the geographic impact of Danny Rischin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny Rischin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny Rischin more than expected).

Fields of papers citing papers by Danny Rischin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danny Rischin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny Rischin. The network helps show where Danny Rischin may publish in the future.

Co-authorship network of co-authors of Danny Rischin

This figure shows the co-authorship network connecting the top 25 collaborators of Danny Rischin. A scholar is included among the top collaborators of Danny Rischin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danny Rischin. Danny Rischin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475. 1 indexed citations
2.
Thai, Alesha, Richard J. Young, Mathias Bressel, et al.. (2024). Characterizing and Targeting of BCL‐2 Family Members in Nasopharyngeal Carcinoma. Head & Neck. 47(3). 867–877.
3.
4.
Harrington, Kevin J., Anthony Kong, Nicolas Mach, et al.. (2020). Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study. Clinical Cancer Research. 26(19). 5153–5161. 83 indexed citations
5.
Solomon, Benjamin, Richard J. Young, Mathias Bressel, et al.. (2018). Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma. Cancer Immunology Research. 6(3). 295–304. 100 indexed citations
6.
Burtness, Barbara, Kevin J. Harrington, Richard Greil, et al.. (2018). KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Annals of Oncology. 29. viii729–viii729. 97 indexed citations
7.
Au‐Yeung, George, Walid J. Azar, Thomas J. Mitchell, et al.. (2016). Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research. 23(7). 1862–1874. 100 indexed citations
8.
Hunter, Francis W., Richard J. Young, Zvi Shalev, et al.. (2015). Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs. Cancer Research. 75(19). 4211–4223. 59 indexed citations
9.
Etemadmoghadam, Dariush, George Au‐Yeung, Meaghan Wall, et al.. (2013). Resistance to CDK2 Inhibitors Is Associated with Selection of Polyploid Cells in CCNE1 -Amplified Ovarian Cancer. Clinical Cancer Research. 19(21). 5960–5971. 90 indexed citations
10.
Le, Quynh‐Thu, Richard Fisher, Kelly S. Oliner, et al.. (2012). Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research. 18(6). 1798–1807. 41 indexed citations
11.
Infante, Jeffrey R., D. Ross Camidge, Linda Mileshkin, et al.. (2012). Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors. Journal of Clinical Oncology. 30(13). 1527–1533. 195 indexed citations
12.
Young, Richard J., Danny Rischin, Richard Fisher, et al.. (2011). Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 20(6). 1230–1237. 70 indexed citations
13.
Rischin, Danny, David C. Bibby, Geoff Chong, et al.. (2011). Clinical, Pharmacodynamic, and Pharmacokinetic Evaluation of BNC105P: A Phase I Trial of a Novel Vascular Disrupting Agent and Inhibitor of Cancer Cell Proliferation. Clinical Cancer Research. 17(15). 5152–5160. 54 indexed citations
14.
Corry, June, Danny Rischin, Sue Cotton, et al.. (2011). Larynx preservation with primary non‐surgical treatment for loco‐regionally advanced larynx cancer. Journal of Medical Imaging and Radiation Oncology. 55(2). 229–235. 8 indexed citations
15.
Peters, Lester J., Brian O’Sullivan, J. Giralt, et al.. (2010). Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02. Journal of Clinical Oncology. 28(18). 2996–3001. 548 indexed citations breakdown →
16.
Rischin, Danny, Richard J. Young, Richard Fisher, et al.. (2010). Prognostic Significance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial. Journal of Clinical Oncology. 28(27). 4142–4148. 571 indexed citations breakdown →
17.
Stewart, J.S.W., Ezra E.W. Cohen, Lisa Licitra, et al.. (2007). A Phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Cancer Research. 67. 3522–3522. 18 indexed citations
18.
Tothill, Richard W., Adam Kowalczyk, Danny Rischin, et al.. (2005). An Expression-Based Site of Origin Diagnostic Method Designed for Clinical Application to Cancer of Unknown Origin. Cancer Research. 65(10). 4031–4040. 153 indexed citations
19.
Fukuoka, Masahiro, Seiji Yano, Giuseppe Giaccone, et al.. (2003). Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 21(12). 2237–2246. 2392 indexed citations breakdown →
20.
Ma, Brigette, June Corry, Danny Rischin, Trevor Leong, & L. J. Peters. (2001). Combined modality treatment for locally advanced squamous-cell carcinoma of the oropharynx in a woman with Bloom’s syndrome: A case report and review of the literature. Annals of Oncology. 12(7). 1015–1017. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacek Jassem Breakdown of academic impact, for papers by Ezra E.W. Cohen Breakdown of academic impact, for papers by Roger B. Cohen Breakdown of academic impact, for papers by Merrill S. Kies Breakdown of academic impact, for papers by Bonnie S. Glisson Breakdown of academic impact, for papers by Andy Trotti Breakdown of academic impact, for papers by Barbara Burtness Breakdown of academic impact, for papers by Lester J. Peters Breakdown of academic impact, for papers by Lisa Licitra Breakdown of academic impact, for papers by M. Bolla
Rankless by CCL
2026